You are here: Home » PTI Stories » National » News
Business Standard

Zydus Cadila gets USFDA nod to market migraine tablets

Press Trust of India  |  New Delhi 

Drug firm today said it has received the final clearance from the US health regulator to market tablets, indicated for patients.

The approval from the Food and Drug Administration (USFDA) is for marketing the tablets in the strengths of 2.5 mg and 5 mg in the US, said in a statement.

The product will be manufactured at the group's facility at Moraiya in Ahmedabad, it added.

tablets are indicated for treatment of It helps in relieving headache, pain, and other symptoms, it said.

The group now has 203 approvals and has so far filed over 330 abbreviated new drug applications (ANDAs), it added.

Shares of Cadila Healthcare, the listed entity of the group, were trading at Rs 366.80 per scrip on BSE, down 1.27 per cent from the previous close.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Thu, July 12 2018. 14:10 IST